Dean, UCSF School of Medicine
Vice Chancellor for Medical Affairs
505 Parnassus Ave, Moffitt Hospital M696
University of California, San Francisco, Box 0110
San Francisco, CA. 94143 – 0110
Phone: (415) 476-9181
- 1970-1975, University of Queensland, Brisbane, Australia, M.B., B.S.
- 1978-1980, Royal Children’s Hospital, Brisbane, Pediatrics Residency
- Monash University, Melbourne, Australia, Neonatal Fellowship, 1981
- University of California San Francisco, San Francisco, CA Neonatal Fellowship, 1982-84
- Royal Australasian College of Pediatrics, 1982
- Lung development and biology
UCSF Program Affiliations
Sam Hawgood, MBBS, has served UC San Francisco for 32 years as a clinician, researcher, teacher, mentor and leader. He succeeded chancellor Susan Desmond-Hellmann on April 1, 2014 as interim chancellor of UCSF. Hawgood has also been serving as dean of the UCSF School of Medicine and as vice chancellor for medical affairs since September of 2009, after assuming the role of interim dean in December of 2007. His distinguished career at UCSF includes serving as chair of the Department of Pediatrics and associate director of the Cardiovascular Research Institute.
Hawgood joined UCSF as a research fellow in 1982, and has maintained his own laboratory since 1984. His focus on the proteins associated with pulmonary surfactant has led to a multidisciplinary Program Project Grant from the National Heart, Lung and Blood Institute, which has supported his work continuously since then and has gained him an international reputation in neonatology research.
Numerous organizations and publications have recognized Hawgood’s scientific contributions over the past few decades. Hawgood is a member of the American Academy of Pediatrics and the American Association of Physicians, and in 2010 was elected to the Institute of Medicine (IOM), part of the National Academy of Sciences.
Hawgood has maintained an active presence in clinical medicine, including serving first as chief of the Division of Neonatology, then as chair of Pediatrics and physician-in-chief of the UCSF Benioff Children’s Hospital prior to becoming dean. He is the president of the UCSF Medical Group, the faculty association that represents more than 1,800 UCSF physicians.
As dean of the School of Medicine, Hawgood oversees an organization with an operating budget of more than $1.7 billion, nearly 8,000 faculty and staff, and around 3,655 medical and graduate students, residents, fellows and postdoctoral scholars. Under his leadership, the school has become the top medical school in the nation in research funding from the National Institutes of Health ($439.6 million in 2013), with many of its departments also leading the nation in their fields, reflecting the caliber of scientific research on campus. In that time, the school also became the only medical school in the nation to rank in the top five in both research- and primary care education (#4 in each), in the US News & World Report’s annual assessment of graduate schools.
The school’s clinical faculty is renowned for world-class medical care through its practice in the top-ranked UCSF Medical Center, UCSF Benioff Children’s Hospital, Langley Porter Psychiatric Institute, San Francisco General Hospital & Trauma Center, and the San Francisco Veterans’ Administration Medical Center.
As interim chancellor, Hawgood oversees the entire $4 billion UCSF enterprise, which also includes top-ranking schools of dentistry, nursing and pharmacy, as well as a graduate division and affiliated hospitals.
A native of Australia, Hawgood graduated medical school with First Class Honors from the University of Queensland in Brisbane. He trained in pediatrics as a resident, followed by specialization in neonatology as a fellow.
For additional information and a list of publications, please see Dr. Hawgood’s page at profiles.ucsf.edu
Sam Hawgood's research activity is focused on the biology of the pulmonary alveolus with a particular emphasis on the structure and function of the pulmonary surfactant apoproteins. The human lung is made up of some 500 million alveoli each with a diameter of 200 microns and a septal wall thickness of only 5-8 microns. The large surface area provided by this foam-like architecture is ideal for rapid respiratory gas exchange but necessitates some unique biological answers to the threat to structural stability posed by the problem of high surface tension and the constant exposure to environmental pollutants, allergens and microbes. Pulmonary surfactant, a lipoprotein secretion of the alveolar epithelial type II cell, stabilizes alveolar structure by reducing the retractile surface forces that would otherwise act to collapse the lung at end expiration. The surfactant apoproteins also act as components of the pulmonary innate defense system protecting the lung from inflammation and infection.
We now know that the surfactant proteins have important roles in the activity of surfactant, particularly the ability to rapidly spread phospholipids at the alveolar surface. The proteins also regulate surfactant turnover and metabolism in the alveolus and play a part in non-antibody mediated response to infection and inflammation in the alveolus. The biology of these proteins is complex and they apparently function as interacting hetero-oligomers to mediate their multiple effects on surfactant biology. At least two of the surfactant proteins, SP-B and SP-C, are present in exogenous surfactants approved for clinical use and fatal human disease has been linked to inherited mutations in both these proteins. This clear link to human disease provides a strong rationale to obtain a detailed understanding of their structure and function.